Please assess the completion status of the following clinical trial:

Trial Title: Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18-75~* Accepted for LVAD implantation by MGH multidisciplinary team~Exclusion Criteria:~* Disorders of the pulmonary artery wall that would preclude placement or correct positioning of RVAD~* Presence of mechanical valves~* Mural thrombosis of the right atrium or vena cava~* Anatomic conditions precluding insertion of the RVAD~* Complicated venous access precluding or complicating device placement (i.e. femoral and jugular thrombosis)~* No evidence of right ventricular dysfunction by echocardiogram

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- prospective interventional cohort (Type: EXPERIMENTAL): The prospective interventional cohort will consist of patients undergoing LVAD implantation at Massachusetts General Hospital. These patients will receive an RVAD (either the ProtekDuo or Impella RP) prior to or during LVAD implantation.
- retrospective control cohort (Type: NO_INTERVENTION): The historical control cohort will consist of retrospective data collection on patients who have undergone LVAD implantation in the past. This group will be age and sex matched with the enrolled prospective interventional patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).